Share on StockTwits

Genocea Biosciences (NASDAQ:GNCA) major shareholder Polaris Venture Management Co. sold 9,660 shares of Genocea Biosciences stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $13.01, for a total transaction of $125,676.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Genocea Biosciences (NASDAQ:GNCA) traded up 0.46% during mid-day trading on Friday, hitting $13.02. The stock had a trading volume of 5,661 shares. Genocea Biosciences has a 1-year low of $10.90 and a 1-year high of $23.99. The stock has a 50-day moving average of $15.86 and a 200-day moving average of $17.10. The company’s market cap is $226.7 million.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings data on Wednesday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. On average, analysts predict that Genocea Biosciences will post $-2.10 earnings per share for the current fiscal year.

Genocea Biosciences, Inc is a United States-based clinical-stage company that develops T cell vaccines.

Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.